Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer’s disease (AD) in China.
The treatment obtained approval in January 2024 for mild cognitive impairment due to AD and mild AD dementia.
Go deeper with GlobalData
China becomes the third country to offer LEQEMBI, following its introduction in the US and Japan.
A monoclonal antibody, LEQEMBI is designed to target and reduce amyloid-beta aggregates in the brain, a characteristic of AD.
The product is specifically engineered to bind to both soluble and insoluble amyloid-beta aggregates, which are implicated in the pathogenesis of Alzheimer’s.
It is the only approved treatment that has demonstrated efficacy in slowing the progression of the disease by impacting these aggregates.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEisai is responsible for the distribution of LEQEMBI in China and is actively engaged in creating awareness and diagnosis pathways for early AD that integrate both digital and traditional services.
The company’s strategy includes partnerships with health insurance companies, health check-up providers and nursing homes to enhance disease awareness and promote early screening.
It is also pioneering the use of blood biomarkers for definitive early AD diagnosis.
Initially, LEQEMBI will be available in China’s private market.
Eisai leads the global development and regulatory submissions for LEQEMBI, while both companies are involved in its co-commercialisation and promotion. Final decision-making authority rests with Eisai.
The approval for LEQEMBI in the US was underpinned by results from Eisai’s Phase III Clarity AD trial.
The trial met its primary endpoint, showing a 27% reduction in clinical decline on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at 18 months when compared to a placebo.
